Tag Archive for: GIP

The obesity pipeline mainly consitsts of 1s5-3rd generation incretin combination therapies expected to decrease the BMI by 15, 17 and 22%, respectively. However, oral formulations and other drugs complementing the effect of GLP1 receptor agonists are coming up.IQVIA
Obesity

FDA approves globally first obesity pill

FDA approves Novo Nordisk’s first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence.

Read more